* LT, liver transplantation; HBV, hepatitis B virus; HCV, hepatitis C virus; HCC, hepatocellular carcinoma; AIH, autoimmune hepatitis; NBNC, non-B non-C; PBC, primary biliary cirrhosis; PSC, primary sclerosing cholangitis; LDLT, living donor liver transplantation; MELD, model for end-stage liver disease
Table 2. Tacrolimus exposure parameters in CYP3A5 expressors and non-expressors before and after the conversion from twice-daily to once-daily extended-release formulation.